Trial reportTransplantation2014
Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation.
Trial report in Transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- Plasticity of the infant immune system during the perinatal period.Nature reviews. Immunology · 2026Review
- Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Convergent evolution of monocyte differentiation in adult skin instructs Langerhans cell identity.Science immunology · 2024Article
- The roles of tissue resident macrophages in health and cancer.Experimental hematology & oncology · 2024Review
- Unravelling monocyte functions: from the guardians of health to the regulators of disease.Discovery immunology · 2024Review
- Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.Frontiers in immunology · 2024Article
- Proliferation of monocytes and macrophages in homeostasis, infection, injury, and disease.Journal of leukocyte biology · 2023Review
- STR typing of skin swabs from individuals after an allogeneic hematopoietic stem cell transplantation.International journal of legal medicine · 2023Article
- Loss of T cell tolerance in the skin following immunopathology is linked to failed restoration of the dermal niche by recruited macrophages.Cell reports · 2022Article
- Monocytes, macrophages, dendritic cells and neutrophils: an update on lifespan kinetics in health and disease.Immunology · 2021Review
- Impact of HLA class I allele-level mismatch on viral infection within 100 days after cord blood transplantation.Scientific reports · 2020Article
- Alternative mechanisms that mediate graft-versus-host disease in allogeneic hematopoietic cell transplants.The Journal of clinical investigation · 2020Article
- Donor monocyte-derived macrophages promote human acute graft-versus-host disease.The Journal of clinical investigation · 2020Article
- Origins and diversity of macrophages in health and disease.Clinical & translational immunology · 2020Review
- Prevention and treatment of relapse after stem cell transplantation by cellular therapies.Bone marrow transplantation · 2019Review
- Human dendritic cell subsets: an update.Immunology · 2018Review
- The immune reconstitution of the skin following sex-mismatched allogeneic haematopoietic stem cell transplant: a prospective case series utilizing fluorescence in situ hybridization and immunohistochemistry.The British journal of dermatology · 2018Article
- Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease.Frontiers in immunology · 2018Review
- Graft versus tumor effects and why people relapse.Hematology. American Society of Hematology. Education Program · 2017Review
- GM-CSF Monocyte-Derived Cells and Langerhans Cells As Part of the Dendritic Cell Family.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundLangerhans cells (LCs) are self-renewing epidermal myeloid cells that can migrate and mature into dendritic cells. Recipient LCs that survive cytotoxic therapy given in preparation for allogeneic hematopoietic cell transplantation may prime donor T cells to mediate cutaneous graft-versus-host disease (GVHD). This possible association, however, has not been investigated in the setting of nonmyeloablative allografting.
methodsWe prospectively studied the kinetics of LC-chimerism after sex-mismatched allogeneic hematopoietic cell transplantation with nonmyeloablative (n=23) or myeloablative (n=25) conditioning. Combined XY-FISH and Langerin-staining was used to assess donor LC-chimerism in skin biopsies obtained on days 28, 56, and 84 after transplant. The degree of donor LC-chimerism was correlated with the development of skin GVHD.
resultsWe observed significantly delayed donor LC-engraftment after nonmyeloablative transplantation compared with other hematopoietic compartments and compared with LC-engraftment after myeloablative conditioning. In most recipients of nonmyeloablative transplants, recipient LCs proliferated in situ, recruitment of donor-LCs was delayed by two months, and full donor LC-chimerism was only reached by day 84 after transplant. Although persistence of host LCs on day-28 after transplant was not predictive for acute or chronic skin GVHD, the recruitment of donor-derived LCs was associated with nonspecific inflammatory infiltrates (P=0.009).
conclusionsThese results show that LCs can self-renew locally but are replaced by circulating precursors even after minimally toxic nonmyeloablative transplant conditioning. Cutaneous inflammation accompanies donor LC-engraftment, but differences in LC conversion-kinetics do not predict clinical or histopathological GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.